Draxis receives full U.S. BrachySeed approval

The U.S. Nuclear Regulatory Commission (NRC) approved BrachySeed iodine-125 brachytherapy seed product to treat prostate cancer. Draxis (DRAX; TSE:DAX) received FDA approval for the product in August,...